vs
Side-by-side financial comparison of Bio-Techne (TECH) and TRIMAS CORP (TRS). Click either name above to swap in a different company.
Bio-Techne is the larger business by last-quarter revenue ($295.9M vs $256.5M, roughly 1.2× TRIMAS CORP). TRIMAS CORP runs the higher net margin — 31.9% vs 12.8%, a 19.0% gap on every dollar of revenue. On growth, TRIMAS CORP posted the faster year-over-year revenue change (3.8% vs -6.4%). Over the past eight quarters, Bio-Techne's revenue compounded faster (4.2% CAGR vs 3.3%).
Bio-Techne Corporation is an American life sciences company that develops, manufactures and sells life science reagents, instruments and services for the research, diagnostic, and bioprocessing markets.
Trimas Corp is a diversified industrial manufacturing enterprise that designs, produces and distributes a wide portfolio of engineered products, including specialized fasteners, aerospace components, custom packaging solutions, and consumer & industrial hardware. It primarily serves aerospace, automotive, construction, consumer goods and industrial sectors, with core operations across North America and selected global markets.
TECH vs TRS — Head-to-Head
Income Statement — Q2 FY2026 vs Q1 FY2026
| Metric | | |
|---|---|---|
| Revenue | $295.9M | $256.5M |
| Net Profit | $38.0M | $81.7M |
| Gross Margin | 64.6% | 12.8% |
| Operating Margin | 18.4% | 5.7% |
| Net Margin | 12.8% | 31.9% |
| Revenue YoY | -6.4% | 3.8% |
| Net Profit YoY | 68.3% | 236.9% |
| EPS (diluted) | $0.24 | $2.03 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q1 26 | — | $256.5M | ||
| Q4 25 | $295.9M | $-140.0M | ||
| Q3 25 | — | $269.3M | ||
| Q2 25 | $317.0M | $274.8M | ||
| Q1 25 | $316.2M | $241.7M | ||
| Q4 24 | $297.0M | $-66.2M | ||
| Q3 24 | $289.5M | $229.4M | ||
| Q2 24 | $306.1M | $240.5M |
| Q1 26 | — | $81.7M | ||
| Q4 25 | $38.0M | $81.7M | ||
| Q3 25 | — | $9.3M | ||
| Q2 25 | $-17.7M | $16.7M | ||
| Q1 25 | $22.6M | $12.4M | ||
| Q4 24 | $34.9M | $5.6M | ||
| Q3 24 | $33.6M | $2.5M | ||
| Q2 24 | $40.6M | $10.9M |
| Q1 26 | — | 12.8% | ||
| Q4 25 | 64.6% | — | ||
| Q3 25 | — | 12.8% | ||
| Q2 25 | 62.7% | 13.8% | ||
| Q1 25 | 67.9% | 13.6% | ||
| Q4 24 | 65.3% | — | ||
| Q3 24 | 63.2% | 15.4% | ||
| Q2 24 | 66.4% | 14.4% |
| Q1 26 | — | 5.7% | ||
| Q4 25 | 18.4% | — | ||
| Q3 25 | — | 6.2% | ||
| Q2 25 | -7.5% | 9.9% | ||
| Q1 25 | 12.2% | 9.0% | ||
| Q4 24 | 16.0% | — | ||
| Q3 24 | 13.8% | 3.6% | ||
| Q2 24 | 15.0% | 7.4% |
| Q1 26 | — | 31.9% | ||
| Q4 25 | 12.8% | -58.4% | ||
| Q3 25 | — | 3.5% | ||
| Q2 25 | -5.6% | 6.1% | ||
| Q1 25 | 7.1% | 5.1% | ||
| Q4 24 | 11.7% | -8.5% | ||
| Q3 24 | 11.6% | 1.1% | ||
| Q2 24 | 13.3% | 4.5% |
| Q1 26 | — | $2.03 | ||
| Q4 25 | $0.24 | $2.01 | ||
| Q3 25 | — | $0.23 | ||
| Q2 25 | $-0.11 | $0.41 | ||
| Q1 25 | $0.14 | $0.30 | ||
| Q4 24 | $0.22 | $0.14 | ||
| Q3 24 | $0.21 | $0.06 | ||
| Q2 24 | $0.26 | $0.27 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $172.9M | $30.0M |
| Total DebtLower is stronger | $260.0M | — |
| Stockholders' EquityBook value | $2.0B | $705.6M |
| Total Assets | $2.5B | $1.5B |
| Debt / EquityLower = less leverage | 0.13× | — |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | — | $30.0M | ||
| Q4 25 | $172.9M | $30.0M | ||
| Q3 25 | — | $33.6M | ||
| Q2 25 | $162.2M | $30.3M | ||
| Q1 25 | $140.7M | $32.7M | ||
| Q4 24 | $177.5M | $23.1M | ||
| Q3 24 | $187.5M | $26.9M | ||
| Q2 24 | $152.9M | $35.0M |
| Q1 26 | — | — | ||
| Q4 25 | $260.0M | $469.2M | ||
| Q3 25 | — | $407.1M | ||
| Q2 25 | $346.0M | $424.5M | ||
| Q1 25 | $330.0M | $434.2M | ||
| Q4 24 | $300.0M | $398.1M | ||
| Q3 24 | $300.0M | $409.9M | ||
| Q2 24 | $319.0M | $427.4M |
| Q1 26 | — | $705.6M | ||
| Q4 25 | $2.0B | $705.6M | ||
| Q3 25 | — | $725.0M | ||
| Q2 25 | $1.9B | $715.3M | ||
| Q1 25 | $2.0B | $686.6M | ||
| Q4 24 | $2.1B | $667.3M | ||
| Q3 24 | $2.1B | $682.8M | ||
| Q2 24 | $2.1B | $675.9M |
| Q1 26 | — | $1.5B | ||
| Q4 25 | $2.5B | $1.5B | ||
| Q3 25 | — | $1.4B | ||
| Q2 25 | $2.6B | $1.4B | ||
| Q1 25 | $2.6B | $1.4B | ||
| Q4 24 | $2.7B | $1.3B | ||
| Q3 24 | $2.7B | $1.4B | ||
| Q2 24 | $2.7B | $1.4B |
| Q1 26 | — | — | ||
| Q4 25 | 0.13× | 0.66× | ||
| Q3 25 | — | 0.56× | ||
| Q2 25 | 0.18× | 0.59× | ||
| Q1 25 | 0.16× | 0.63× | ||
| Q4 24 | 0.14× | 0.60× | ||
| Q3 24 | 0.14× | 0.60× | ||
| Q2 24 | 0.15× | 0.63× |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | — | $117.5M |
| Free Cash FlowOCF − Capex | — | $36.8M |
| FCF MarginFCF / Revenue | — | 14.4% |
| Capex IntensityCapex / Revenue | — | 18.9% |
| Cash ConversionOCF / Net Profit | — | 1.44× |
| TTM Free Cash FlowTrailing 4 quarters | — | $109.7M |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | — | $117.5M | ||
| Q4 25 | — | $41.5M | ||
| Q3 25 | — | $36.5M | ||
| Q2 25 | $98.2M | $30.3M | ||
| Q1 25 | $41.1M | $9.2M | ||
| Q4 24 | $84.3M | $27.1M | ||
| Q3 24 | $63.9M | $22.0M | ||
| Q2 24 | $75.5M | $18.4M |
| Q1 26 | — | $36.8M | ||
| Q4 25 | — | $36.8M | ||
| Q3 25 | — | $22.8M | ||
| Q2 25 | $93.3M | $13.2M | ||
| Q1 25 | $31.0M | $-3.8M | ||
| Q4 24 | $77.5M | $12.1M | ||
| Q3 24 | $54.7M | $10.2M | ||
| Q2 24 | $57.5M | $7.5M |
| Q1 26 | — | 14.4% | ||
| Q4 25 | — | -26.3% | ||
| Q3 25 | — | 8.5% | ||
| Q2 25 | 29.4% | 4.8% | ||
| Q1 25 | 9.8% | -1.6% | ||
| Q4 24 | 26.1% | -18.3% | ||
| Q3 24 | 18.9% | 4.4% | ||
| Q2 24 | 18.8% | 3.1% |
| Q1 26 | — | 18.9% | ||
| Q4 25 | — | -3.4% | ||
| Q3 25 | — | 5.1% | ||
| Q2 25 | 1.5% | 6.2% | ||
| Q1 25 | 3.2% | 5.4% | ||
| Q4 24 | 2.3% | -22.6% | ||
| Q3 24 | 3.2% | 5.2% | ||
| Q2 24 | 5.9% | 4.5% |
| Q1 26 | — | 1.44× | ||
| Q4 25 | — | 0.51× | ||
| Q3 25 | — | 3.92× | ||
| Q2 25 | — | 1.81× | ||
| Q1 25 | 1.82× | 0.74× | ||
| Q4 24 | 2.42× | 4.80× | ||
| Q3 24 | 1.90× | 8.71× | ||
| Q2 24 | 1.86× | 1.68× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
TECH
| Diagnostics And Spatial Biology | $81.2M | 27% |
| EMEA Excluding UK | $75.4M | 25% |
| Other | $42.4M | 14% |
| Instruments | $29.6M | 10% |
| APAC Excluding Greater China | $22.7M | 8% |
| Services | $22.3M | 8% |
| GB | $13.7M | 5% |
| Royalty | $8.5M | 3% |
TRS
Segment breakdown not available.
